BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 24095675)

  • 1. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
    Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model.
    Sirenko O; Grimm FA; Ryan KR; Iwata Y; Chiu WA; Parham F; Wignall JA; Anson B; Cromwell EF; Behl M; Rusyn I; Tice RR
    Toxicol Appl Pharmacol; 2017 May; 322():60-74. PubMed ID: 28259702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds.
    Lu HR; Whittaker R; Price JH; Vega R; Pfeiffer ER; Cerignoli F; Towart R; Gallacher DJ
    Toxicol Sci; 2015 Dec; 148(2):503-16. PubMed ID: 26358003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic Assays for Characterizing Compound Effects on Induced Pluripotent Stem Cell-Derived Cardiac Spheroids.
    Sirenko O; Hancock MK; Crittenden C; Hammer M; Keating S; Carlson CB; Chandy G
    Assay Drug Dev Technol; 2017; 15(6):280-296. PubMed ID: 28837356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells.
    Sirenko O; Crittenden C; Callamaras N; Hesley J; Chen YW; Funes C; Rusyn I; Anson B; Cromwell EF
    J Biomol Screen; 2013 Jan; 18(1):39-53. PubMed ID: 22972846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of extracellular field potential and Ca
    Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
    J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
    Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
    Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
    Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
    Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.
    Ovics P; Regev D; Baskin P; Davidor M; Shemer Y; Neeman S; Ben-Haim Y; Binah O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023024
    [No Abstract]   [Full Text] [Related]  

  • 14. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
    Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
    Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
    Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
    Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between constituents of energy drinks and beating parameters in human induced pluripotent stem cell (iPSC)-Derived cardiomyocytes.
    Luo YS; Chen Z; Blanchette AD; Zhou YH; Wright FA; Baker ES; Chiu WA; Rusyn I
    Food Chem Toxicol; 2021 Mar; 149():111979. PubMed ID: 33450301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.